Comparative Pharmacology
Head-to-head clinical analysis: APONVIE versus MAREZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APONVIE versus MAREZINE.
APONVIE vs MAREZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
APONVIE (pemigatinib) is a selective fibroblast growth factor receptor (FGFR) inhibitor. It binds to and inhibits FGFR1, FGFR2, and FGFR3, thereby suppressing FGFR signaling and reducing proliferation and survival of tumor cells with FGFR alterations.
Marezine (cyclizine) is a piperazine-derivative histamine H1-receptor antagonist with central anticholinergic and antiemetic activity. It competitively blocks H1 receptors in the vestibular apparatus and the chemoreceptor trigger zone (CTZ), suppressing nausea and vomiting. It also has antimuscarinic effects on the vomiting center.
APONVIE is not a recognized drug; no dosing information available.
50 mg intramuscularly or intravenously every 4 to 6 hours as needed for motion sickness; 50 mg orally 30 to 60 minutes before travel, then every 4 to 6 hours up to 150 mg/24h.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours in healthy adults; prolonged to 24–36 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 4-6 hours in adults; prolonged to 8-12 hours in elderly or hepatic impairment
APONVIE is primarily excreted renally as unchanged drug (approx. 70%) and via biliary/fecal routes (approx. 30%).
Renal: 70-80% as unchanged drug and metabolites; fecal: ~20%; biliary: minor
Category C
Category C
Antiemetic
Antiemetic